350 related articles for article (PubMed ID: 26321489)
41. Oral medication prescription practices of tertiary-based specialists for dystonia in children with cerebral palsy.
Harvey A; Reddihough D; Scheinberg A; Williams K
J Paediatr Child Health; 2018 Apr; 54(4):401-404. PubMed ID: 29105865
[TBL] [Abstract][Full Text] [Related]
42. [Quality of life in cerebral palsy children treated with intrathecal baclofen pump implantation in parents' opinion].
Borowski A; Pruszczyński B; Miller F; Synder M
Chir Narzadow Ruchu Ortop Pol; 2010; 75(5):318-22. PubMed ID: 21853903
[TBL] [Abstract][Full Text] [Related]
43. A critical evaluation of oral baclofen in pediatric patients with cerebral palsy.
McLaughlin MJ; Fisher MT
J Pediatr Rehabil Med; 2023; 16(1):3-9. PubMed ID: 36872802
[No Abstract] [Full Text] [Related]
44. Efficacy and tolerability of eperisone and baclofen in spastic palsy: a double-blind randomized trial.
Bresolin N; Zucca C; Pecori A
Adv Ther; 2009 May; 26(5):563-73. PubMed ID: 19458926
[TBL] [Abstract][Full Text] [Related]
45. Baclofen in the treatment of cerebral palsy.
Albright AL
J Child Neurol; 1996 Mar; 11(2):77-83. PubMed ID: 8881981
[TBL] [Abstract][Full Text] [Related]
46. Intrathecal baclofen in the management of spasticity due to cerebral palsy.
Vloeberghs M; Keetley R; Morton R
Pediatr Rehabil; 2005; 8(3):172-9. PubMed ID: 16087551
[TBL] [Abstract][Full Text] [Related]
47. Experience with external pump trial prior to implantation for intrathecal baclofen in ambulatory patients with spastic cerebral palsy.
Bleyenheuft C; Filipetti P; Caldas C; Lejeune T
Neurophysiol Clin; 2007; 37(1):23-8. PubMed ID: 17418354
[TBL] [Abstract][Full Text] [Related]
48. [Spasticity in children cerebral palsy: diagnosis and treatment strategies].
Kurenkov AL; Batysheva TT; Vinogradov AV; Ziuziaeva EK
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(7 Pt 2):24-8. PubMed ID: 23330188
[TBL] [Abstract][Full Text] [Related]
49. Long-term follow-up on continuous intrathecal Baclofen therapy in non-ambulant children with intractable spastic Cerebral Palsy.
Vles GF; Soudant DL; Hoving MA; Vermeulen RJ; Bonouvrié LA; van Oostenbrugge RJ; Vles JS
Eur J Paediatr Neurol; 2013 Nov; 17(6):639-44. PubMed ID: 23871360
[TBL] [Abstract][Full Text] [Related]
50. Intrathecal baclofen use in adults with cerebral palsy.
Krach LE
Dev Med Child Neurol; 2009 Oct; 51 Suppl 4():106-12. PubMed ID: 19740217
[TBL] [Abstract][Full Text] [Related]
51. Oral baclofen and clonidine for treatment of spasticity in children.
Lubsch L; Habersang R; Haase M; Luedtke S
J Child Neurol; 2006 Dec; 21(12):1090-2. PubMed ID: 17156708
[TBL] [Abstract][Full Text] [Related]
52. Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity.
Dai AI; Aksoy SN; Demiryürek AT
J Child Neurol; 2016 Feb; 31(2):184-9. PubMed ID: 25999301
[TBL] [Abstract][Full Text] [Related]
53. 'Effects of oral baclofen on children with cerebral palsy'.
Vargus-Adams JN; Michaud LJ; Kinnett DG; McMahon MA; Cook FE
Dev Med Child Neurol; 2004 Nov; 46(11):787. PubMed ID: 15540642
[No Abstract] [Full Text] [Related]
54. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
Groves L; Shellenberger MK; Davis CS
Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
[TBL] [Abstract][Full Text] [Related]
55. Intracerebroventricular baclofen therapy improves function and quality of life in a child with severe cerebral palsy.
Assumpcao de Monaco B; Fruett da Costa PR; Franceschini PR
Childs Nerv Syst; 2023 Dec; 39(12):3639-3642. PubMed ID: 37515719
[TBL] [Abstract][Full Text] [Related]
56. Pharmacotherapy of spasticity in children with cerebral palsy.
Chung CY; Chen CL; Wong AM
J Formos Med Assoc; 2011 Apr; 110(4):215-22. PubMed ID: 21540003
[TBL] [Abstract][Full Text] [Related]
57. Pharmacologic management of spasticity in cerebral palsy.
Mooney JF; Koman LA; Smith BP
J Pediatr Orthop; 2003; 23(5):679-86. PubMed ID: 12960637
[No Abstract] [Full Text] [Related]
58. Pharmacological management of abnormal tone and movement in cerebral palsy.
Lumsden DE; Crowe B; Basu A; Amin S; Devlin A; DeAlwis Y; Kumar R; Lodh R; Lundy CT; Mordekar SR; Smith M; Cadwgan J
Arch Dis Child; 2019 Aug; 104(8):775-780. PubMed ID: 30948360
[TBL] [Abstract][Full Text] [Related]
59. [Treatment of spasticity with the intrathecal administration of baclofen].
Lazorthes Y; Sallerin B; Verdié JC; Casaux J; Caraoué F; Sol JC
Neurochirurgie; 1998 Sep; 44(3):201-8. PubMed ID: 9827437
[TBL] [Abstract][Full Text] [Related]
60. Continuously infused intrathecal baclofen over 12 months for spastic hypertonia in adolescents and adults with cerebral palsy.
Meythaler JM; Guin-Renfroe S; Law C; Grabb P; Hadley MN
Arch Phys Med Rehabil; 2001 Feb; 82(2):155-61. PubMed ID: 11239304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
